Every 424B that Horizon Technology Finance Corporation (HRZN) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow HRZN and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full HRZN filings page.
Horizon Technology Finance Corporation and Monroe Capital Corporation filed Supplement No. 2 to their Joint Proxy Statement/Prospectus updating disclosures about the proposed asset sale and merger and announcing enhanced near-term cash distributions. The supplement describes a Supplemental MRCC Distribution of $13.0 million and proposed HRZN Supplemental Distributions to use undistributed taxable earnings for two quarters following closing, subject to board declaration and closing conditions.
The supplement also discloses that following HRZN’s March 3, 2026 announcement of a reduced quarterly distribution of $0.18 per share, HRZN’s closing price fell from $6.11 to $4.69 on March 4, 2026, and MRCC’s closing price fell from $6.03 to $4.84 on March 4, 2026. The supplement states the Special Committees and Boards supported announcing the supplemental distributions and describes related fiduciary deliberations and tax treatment of the Supplemental MRCC Distribution.
Horizon Technology Finance Corporation filed Supplement No. 1 dated March 5, 2026 to the joint proxy statement/prospectus dated January 16, 2026. The supplement amends, supplements or modifies information in the combined prospectus and definitive joint proxy statement of HRZN and Monroe Capital Corporation.
The supplement incorporates by reference previously filed SEC documents and states that the Joint Proxy Statement/Prospectus is available free of charge at www.sec.gov or via the HRZN and MRCC investor relations contact details provided in the text.
Horizon Technology Finance Corporation and Monroe Capital Corporation are asking stockholders to approve a two‑step transaction in which MRCC will first sell all of its investment assets for cash to Monroe Capital Income Plus Corporation, then merge into HRZN, with HRZN as the surviving BDC.
MRCC will receive cash equal to the fair value of its assets, use it to repay liabilities and distribute undistributed net investment income, then MRCC stockholders will receive HRZN common stock based on a NAV‑driven exchange ratio calculated shortly before closing, with cash paid instead of fractional shares. Separate special meetings on March 13, 2026 will seek HRZN stockholder approval of issuing HRZN shares for the merger and electing one Class I director, and MRCC stockholder approval of both the asset sale and the merger; each board, following independent special committee review and financial advisor opinions, unanimously recommends voting in favor of its respective proposals. The HRZN adviser has agreed to a $4.0 million management and incentive fee waiver over four quarters after closing, and the merger is intended to be tax‑free for MRCC stockholders except for cash in lieu of fractional shares.
Horizon Technology Finance Corporation is offering $57.5 million of unsecured 7.00% notes maturing on December 15, 2028. The notes are priced at 100% of principal, pay interest semi-annually each June 15 and December 15 starting June 15, 2026, and are issued in minimum denominations of $2,000.
The notes rank equally with the company’s other unsecured, unsubordinated debt and are effectively and structurally subordinated to secured and subsidiary-level obligations. Horizon estimates net proceeds of about $56.4 million, which it intends to use to repay indebtedness, including its 4.875% notes due 2026, and for general corporate purposes. The notes are callable at a make-whole premium before June 15, 2028 and at par thereafter, and investors may require repurchase at 100% of principal upon a Change of Control Repurchase Event.